Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97531 | 0.81 | LMNA (0.54) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL7398355 | 0.81 | GRM5 (0.50) | GRM5WDR5LMNAMAPK1HTT | |
| SCHEMBL5757417 | 0.81 | MAOB (0.51) | GRM5WDR5LMNAMAPK1HTT | |
| SCHEMBL6213159 | 0.79 | SOD1 (0.47) | GRM5 | |
| SCHEMBL3402920 | 0.78 | WDR5 (0.47) | GRM5WDR5LMNAMAPK1HTT | |
| SCHEMBL2096238 | 0.78 | WDR5 (0.55) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL9808215 | 0.77 | LMNA (0.67) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL7771384 | 0.77 | CHRNB2 (0.50) | DRD2DRD4 | |
| SCHEMBL756665 | 0.77 | ACHE (0.50) | LMNAHTTSMN1; SMN2DRD2DRD4 | |
| SCHEMBL11686736 | 0.77 | TP53 (0.53) | LMNAMAPK1HTTSMN1; SMN2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0469888-B1 | Amidobenzenes | ICI PLC (GB) | 1994-09-28 | — | — | EP | claimed |
| US-5250570-A | Aldose reductase inhibitors for controlling side effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-05 | — | — | US | claimed |
| EP-0469888-A1 | Amidobenzenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-05 | — | — | EP | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| EP-0469888-A1 | Amidobenzenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0209352-B1 | PROCESS AND INTERMEDIATES FOR BETA-LACTAM ANTIBIOTICS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1991-05-02 | — | — | EP | disclosed |
| US-4870169-A | Intermediates for beta-lactam antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-09-26 | — | — | US | disclosed |
| US-4775752-A | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-10-04 | — | — | US | disclosed |
| US-4734495-A | Process and intermediates for beta-lactam antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-03-29 | — | — | US | disclosed |
| US-4665171-A | CARBACEPHALOSPORINS | HARVARD UNIVERSITY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0209352-A2 | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-01-21 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GRM5 897/4885WDR5 2342/4885LMNA 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.